Immunocore (NASDAQ:IMCR – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $100.00 price objective on the stock. HC Wainwright‘s price objective would suggest a potential upside of 219.69% from the company’s current price.
A number of other equities analysts have also recently commented on IMCR. Morgan Stanley set a $43.00 target price on Immunocore in a report on Friday, August 7th. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Mizuho raised their price target on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. JPMorgan Chase & Co. began coverage on Immunocore in a research report on Friday, August 21st. They set an “overweight” rating and a $50.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $56.38.
Get Our Latest Analysis on Immunocore
Immunocore Price Performance
NASDAQ IMCR traded up $0.30 during trading on Monday, reaching $31.28. The company’s stock had a trading volume of 197,925 shares, compared to its average volume of 457,905. The stock has a market capitalization of $1.61 billion, a PE ratio of -84.54 and a beta of 0.81. Immunocore has a one year low of $27.50 and a one year high of $40.71. The firm has a fifty day moving average of $32.82 and a 200 day moving average of $31.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44.
Immunocore (NASDAQ:IMCR – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. Analysts expect that Immunocore will post 0.04 EPS for the current fiscal year.
Hedge Funds Weigh In On Immunocore
Several large investors have recently bought and sold shares of the business. Crossmark Global Holdings Inc. boosted its position in shares of Immunocore by 13.7% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 41,387 shares of the company’s stock worth $1,254,000 after acquiring an additional 4,971 shares in the last quarter. Juncture Wealth Strategies LLC purchased a new position in shares of Immunocore during the third quarter worth about $207,000. Engineers Gate Manager LP grew its holdings in shares of Immunocore by 334.3% during the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after purchasing an additional 46,435 shares during the last quarter. denkapparat Operations GmbH purchased a new position in shares of Immunocore during the second quarter worth about $209,000. Finally, Braidwell LP purchased a new position in shares of Immunocore during the second quarter worth about $16,552,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.
About Immunocore
Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.
The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.
Featured Articles
- Five stocks we like better than Immunocore
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
